Mangiferin and organ fibrosis: A mini review.

Abstract

Fibrosis is the end stage of many chronic diseases, which results in organ function failure and high mortality. Mangiferin is a major constituent in mango and other 16 plants, and has been shown a variety of pharmacological effects, such as antioxidant, antibacterial, anti-tumor, anti-inflammation. The emerging evidence has shown that mangiferin can improve renal interstitial fibrosis, pulmonary fibrosis, myocardial fibrosis and hepatic fibrosis through the inhibition of inflammation, oxidative stress and fibrogenesis effects, indicating that mangiferin is promising therapeutic choice for organ fibrosis. The aim of this review is to summarize the therapeutic effects of mangiferin on fibrosis of various organs and the underlying mechanisms.

• Authors: Lijun Zhang, Cheng Huang, Shengjie Fan
• Journal: BioFactors (Oxford, England) (Biofactors) Vol. 47 Issue 1 Pg. 59-68 (Jan 2021) ISSN: 1872-8081 [Electronic] Netherlands
• PMID: 33217771 (Publication Type: Journal Article, Review)
• Copyright: © 2020 International Union of Biochemistry and Molecular Biology.

Chemical References

• Anti-Inflammatory Agents
• Antioxidants
• Xanthones
• mangiferin

Topics

• Animals
• Anti-Inflammatory Agents (chemistry, pharmacokinetics, pharmacology, therapeutic use)
• Antioxidants (chemistry, pharmacokinetics, pharmacology, therapeutic use)
• Fibrosis (drug therapy, etiology)
• Humans
• Kidney (pathology)
• Liver Cirrhosis (drug therapy)
• Mice
• Myocardium (pathology)
• Pulmonary Fibrosis (drug therapy)
• Rats
• Xanthones (chemistry, pharmacokinetics, pharmacology, therapeutic use)